Services Database COVID-19 Therapeutics for Non-Hospitalised Patients Pilot

Service Aim and Intended Outcome

• To ensure the timely access and efficiency of supply of COVID-19 oral antiviral therapeutics for the treatment of COVID-19 to eligible patients
• To participate in the development and provision of a local pathway ensuring routine access to COVID-19 oral medication treatment for individuals at highest risk of hospitalisation
• To offer support and advice to patients and their carers on the oral antiviral COVID-19 therapeutics supplied to treat COVID-19.
• To act as a point of contact for patients during their course of treatment and liaise with local services as deemed appropriate.
• Approach to health inequalities – local pathway to ensure equitable access to services Data and reporting requirements – ensure effective monitoring and data sharing to support service improvement and commissioning of service after pilot
• This service will require the pharmacy to maintain the required stock of Covid Therapeutic Medication in line with the agreed list in Appendix 1. The stock list may be subject to changes in line with national or local guidance

• The pharmacy contractor shall ensure that pharmacists and staff involved in the provision of the service are appropriately trained, are aware of and operate within local procedures and guideline
• NEL ICB and the current service provider will work with NHS England to provide relevant training.
• Pharmacists dispensing this medication must attend NEL ICB training as directed
• The contractor has a duty to ensure that pharmacists and dispensary staff involved in the provision of the service are aware the medication being dispensed as per the Summary of Product Characteristics:

1. Paxlovid - https://www.medicines.org.uk/emc/product/13145
2. Molnupiravir - https://www.medicines.org.uk/emc/product/13044